Aptose Biosciences Inc  

(Public, NASDAQ:APTO)   Watch this stock  
Find more results for OTC:LRUSF
0.00 (0.00%)
Oct 21 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 1.82 - 1.95
52 week 1.82 - 6.40
Open 1.89
Vol / Avg. 76,285.00/84,140.00
Mkt cap 24.64M
P/E     -
Div/yield     -
EPS -1.15
Shares 13.04M
Beta 0.94
Inst. own 32%
Nov 8, 2016
Q3 2016 Aptose Biosciences Inc Earnings Release (Estimated) - 4:00PM EST - Add to calendar
Oct 13, 2016
Aptose Biosciences Inc Conference Call to Discuss on FDA Clinical Hold of APTO-253 - Webcast
Aug 11, 2016
Aptose Biosciences Inc at Canaccord Genuity Growth Conference - Webcast
Aug 9, 2016
Q2 2016 Aptose Biosciences Inc Earnings Call
Aug 9, 2016
Q2 2016 Aptose Biosciences Inc Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q2 (Jun '16) 2015
Net profit margin - -
Operating margin - -
EBITD margin - -
Return on average assets -151.35% -55.35%
Return on average equity -172.57% -60.73%
Employees 22 -
CDP Score - -


5955 Airport Rd Suite 228
+1-647-4799828 (Phone)
+1-416-7982200 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


Aptose Biosciences Inc. (Aptose) is a clinical-stage biotechnology company. The Company is engaged in the development of anticancer drugs that target specific epigenetic processes and signal transduction abnormalities that underlie a particular life-threatening malignancy. Its product pipeline includes cancer drug candidates that exert activity as stand-alone agents and that enhance the activities of other anticancer agents without causing overlapping toxicities. The Company develops therapeutics focused on epigenetic processes and signal transduction abnormalities at the edge of cancer research, coupled with companion diagnostics to identify the optimal patient population for its products. The Company's APTO-253 is a small molecule that can induce expression of the genes that codes for the Kruppel-like factor 4 (KLF4) master transcription factor and the p21 cell cycle inhibitor protein.

Officers and directors

William Glenn Rice Chairman of the Board, President, Chief Executive Officer
Bio & Compensation  - Reuters
Gregory Kwok Lee Chow Chief Financial Officer, Senior Vice President
Bio & Compensation  - Reuters
Avanish Vellanki Senior Vice President, Chief Business Officer
Bio & Compensation  - Reuters
Denis R. Burger Ph.D. Independent Director
Age: 70
Bio & Compensation  - Reuters
Erich M. Platzer M.D., Ph.D. Independent Director
Bio & Compensation  - Reuters
Bradley Thompson Independent Director
Bio & Compensation  - Reuters
Mark D. Vincent M.D. Independent Director
Bio & Compensation  - Reuters
Warren Whitehead Independent Director
Bio & Compensation  - Reuters